Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&D Systems™ AI-Engineered Designer Protein portfolio AI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing MINNEAPOLIS, July 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents.

prnewswire.com - 2026-07-08 06:30:00

BALA CYNWYD, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

globenewswire.com - 2026-07-06 12:17:00

MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.

globenewswire.com - 2026-07-02 05:31:48

MILWAUKEE, July 02, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck.

globenewswire.com - 2026-07-02 05:31:00

BALA CYNWYD, Pa., June 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

globenewswire.com - 2026-06-30 13:13:00

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Bio-Techne Corporation (NasdaqGS: TECH) to Merck KGaA. Under the terms of the proposed transaction, shareholders of Bio-Techne will receive $73.00 in cash for each share of Bio-Techne that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.

businesswire.com - 2026-06-29 16:21:00

Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 29, 2026

gurufocus.com - 2026-06-29 14:00:00

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

prnewswire.com - 2026-06-29 13:59:00

ANTWERP, Belgium, 29 June 2026, 08:00 CET – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) has sold two Suezmaxes, generating a capital gain of approximately 100.5 million USD.

globenewswire.com - 2026-06-29 01:57:00

NEW YORK, June 26, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Bio-Techne Corporation (NASDAQ: TECH ) related to its sale to Merck KGaA.

prnewswire.com - 2026-06-26 14:24:00

Bio-Techne Corporation (TECH) M&A Call Transcript

seekingalpha.com - 2026-06-26 09:02:34

On June 25, 2026, investors tracked deal progress as Bio-Techne shares responded to the proposed buyout terms.

fool.com - 2026-06-25 17:23:42

Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026

gurufocus.com - 2026-06-25 14:00:00

MILWAUKEE, June 25, 2026 /PRNewswire/ -- Ademi LLP is investigating Bio-Techne (NASDAQ: TECH) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

prnewswire.com - 2026-06-25 10:00:00

Merck KGaA (OTC:MKKGY) (OTC:MKGAF) on Thursday agreed to acquire Bio-Techne Corporation (NASDAQ:TECH) in an all-cash transaction valued at approximately $11.3 billion, as the German science and technology company seeks to expand its presence across life science research, diagnostics, and bioprocessing markets.

benzinga.com - 2026-06-25 09:34:03

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Bio-Techne Corporation (NASDAQ: TECH) to Merck KGaA for $73.00 per share in cash. Halper Sadeh encourages Bio-Techne shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Bio-Techne and its board of directors violat.

businesswire.com - 2026-06-25 07:48:00

Bio-Techne stock jumps, with Germany's Merck KGaA buying the company at a 24% premium.

barrons.com - 2026-06-25 07:18:00

Purchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion) Proposed acquisition expected to be immediately accretive to sales growth and EBITDA pre margin post-closing, and EPS pre accretive by year 3 after closing U.S.-based Bio-Techne to bring portfolio with industry-leading multi-omics offering, analytical technologies and integrated workflow solutions across the scientific journey Would deliver on growth agenda of Merck KGaA, Darmstadt, Germany, by expanding presence in high-growth, next-generation life sciences markets and further strengthening the position as a leader along the full life science value chain Would add complementary strengths across research, bioprocessing and advanced therapeutics, bolstering the offering of Merck KGaA, Darmstadt, Germany, in next-generation biology Synergistic platform would broaden offerings, accelerate innovation pipeline of Merck KGaA, Darmstadt, Germany, and increase Bio-Techne's geographic and omnichannel access for customers Merck KGaA, Darmstadt, Germany, expects annual cost synergies of approximately EUR 140 million, which are anticipated to be fully realized by year 3 after closing DARMSTADT, Germany and MINNEAPOLIS, June 25, 2026 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, and Bio-Techne Corporation (NASDAQ: TECH), a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, today entered into a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, will, subject to customary closing conditions, acquire Bio-Techne for US$73 per share in cash, representing a total enterprise value of approximately US$11.3 billion (EUR 9.9 billion), a 36% premium to Bio-Techne's one-month volume weighted average trading price. The transaction would bring together two highly complementary and leading life sciences organizations, uniquely positioned to support customers across the full spectrum of life science workflows – from discovery and translational research through development, testing and commercial manufacturing.

prnewswire.com - 2026-06-25 06:10:00

Merck KGaA has ​agreed to acquire ‌biotech firm Bio-Techne Corp ​for $73 per ​share in cash, ⁠the German ​science and ​healthcare firm said in a statement ​on ​Thursday.

reuters.com - 2026-06-25 06:09:35

Merck KGaA offered $73 a share in cash to buy Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier's closing price Wednesday.

wsj.com - 2026-06-25 06:08:00

Antwerp, June 22, 2026 (GLOBE NEWSWIRE) -- CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs : CMBTO) and Fortescue have signed a milestone agreement for the charter of up to 12 ammonia-capable vessels, marking a significant step towards decarbonising global shipping and advancing the adoption of ammonia as a shipping fuel .

globenewswire.com - 2026-06-22 02:22:00

The Lanier Law Firm attorney Mark Lanier discusses Roblox's new safety measures, online child protection and Florida's lawsuit against TikTok on ‘Varney & Co.' #foxbusiness #varneyandco 00:00 — Mark Lanier Says Roblox Safeguards Don't Go Far Enough 01:00 — Parents, Phones, and the Growing Child Safety Challenge 01:42 — Florida Targets TikTok Over Child Safety Concerns 03:06 — States Escalate Legal Pressure on OpenAI and Big Tech 04:00 — AI Safety, Minors, and the Future of Tech Regulation

youtube.com - 2026-06-16 14:00:03

CMBT.TECH transformed post-Golden Ocean merger, evolving from a tanker-focused play to a diversified shipping platform with over 250 vessels. Current tanker and dry bulk markets are both robust, driving strong Q1 2026 results, but investors now face multi-cycle risk exposure. Q1 profit of $368.8M was boosted by $267.4M in vessel disposals, reflecting proactive capital management amid favorable market conditions.

seekingalpha.com - 2026-06-13 03:35:16

Techne (TECH) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-05 12:35:35

New integrated workflow combines icIEF fractionation and mass photometry Enables direct characterization of aggregation and size within icIEF-resolved charge variants Four-hour workflow reduces development risk and accelerates biosimilar manufacturing MINNEAPOLIS and OXFORD, England, June 4, 2026 /PRNewswire/ -- Bio‑Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass photometry technology, today announced a first‑of‑its‑kind integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars. By combining R&D Systems MauriceFlex™ imaged capillary isoelectric focusing (icIEF) fractionation system with Refeyn's TwoMP mass photometry platform, researchers can directly correlate charge heterogeneity with molecular weight and aggregation at single‑molecule resolution in a streamlined four‑hour workflow.

prnewswire.com - 2026-06-04 06:30:00

Antwerp, May 21, 2026 (GLOBE NEWSWIRE) -- CMB.TECH  NV (“ CMBT ”, “ CMB.TECH ” or “the  c ompany”)  (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo  Børs : CMBTO) announces that today the General Meeting of Shareholders has approved the annual accounts for the year ended 31 December 202 5 . All other resolutions proposed by CMB.TECH's Supervisory Board  were also  approved.   Re appointment of Supervisory Board members  for a period of  three  years

globenewswire.com - 2026-05-21 11:39:00

CMB.TECH NV (CMBT) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-19 14:30:44

CMB.TECH NYSE: CMBT reported a strong first quarter of 2026, with management highlighting higher revenue, reduced leverage, lower financing costs and substantial gains from vessel sales during an earnings call titled “Firing on All Cylinders.”

marketbeat.com - 2026-05-19 11:08:29

CMB.TECH ANNOUNCES Q1 2026 RESULTS FIRING ON ALL CYLINDERS ANTWERP, Belgium, 19 May 2026 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) reported its unaudited financial results today for the first quarter ended 31 March 2026. HIGHLIGHTS Financial highlights: Profit for the period of USD 368.8 million in Q1 2026.

globenewswire.com - 2026-05-19 01:01:00

Bio-Techne Corporation (TECH) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 16:30:47

ANTWERP, Belgium, 7 May 2026 – CMB.TECH NV  (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMBT”, “CMB.TECH” or “the Company”) will release its first quarter 2026 earnings prior to market opening on Tuesday 19 May 2026 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter.

globenewswire.com - 2026-05-07 01:58:00

Bio-Techne Corporation (TECH) Q3 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-06 14:01:15

Bio-Techne slips after Q3 EPS miss and revenue decline, despite operating margin expansion and strong growth in key segments.

zacks.com - 2026-05-06 12:47:16

Techne (TECH) came out with quarterly earnings of $0.53 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.56 per share a year ago.

zacks.com - 2026-05-06 08:45:37

Biotech firm Bio-Techne on Wednesday missed Wall Street estimates for third-quarter revenue, as cuts to U.S. ​academic funding weighed on demand for its drug-development ‌products.

reuters.com - 2026-05-06 07:21:10

MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2026. Third Quarter FY2026 Highlights Reported and organic revenue declined 2% to $311.4M, negatively impacted by prior‑year GMP fast‑track orders and timing of large Commercial Supply shipments GAAP EPS increased to $0.32 from $0.14; adjusted EPS was $0.53, down from $0.56 Large pharma delivered the sixth consecutive quarter of double‑digit growth, offset by a continued lag in spending by emerging biotech; U.S. academic markets stabilized with low‑single‑digit growth Growth vectors performed well, with mid‑single‑digit growth in Proteomic Analysis instruments, mid‑teens growth in Spatial Biology, and nearly 50% growth in GMP proteins excluding fast‑track customers "The Bio‑Techne team delivered solid execution amid a mixed end‑market environment," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne.

prnewswire.com - 2026-05-06 06:30:00

MINNEAPOLIS, May 6, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2026. The quarterly dividend will be payable May 29, 2026, to all common shareholders of record on May 18, 2026.

prnewswire.com - 2026-05-06 06:30:00

MINNEAPOLIS, May 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026, at 9:20 a.m. PDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

prnewswire.com - 2026-05-04 07:00:00

TECH gears up for Q3 results with modest revenue growth expected as biotech funding trends and product momentum shape the outlook.

zacks.com - 2026-04-29 11:07:11

ANTWERP, Belgium, 21 April 2026, 08:00 a.m. CET – CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) (NYSE: CMBT, Euronext Brussels: CMBT en Euronext Oslo Børs: CMBTO) published its annual report in accordance with Belgian law and submits Form 20-F for the year ended on 31 December 2025. CMB.TECH further invites its shareholders to participate in the Annual General Meeting and the Special General Meeting that will be held on Thursday 21 May 2026.

globenewswire.com - 2026-04-21 01:57:00

Shares of Bio-Techne Corp (NASDAQ: TECH - Get Free Report) have been assigned an average rating of "Moderate Buy" from the fourteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, nine have assigned a buy

defenseworld.net - 2026-04-17 01:44:50

Bio-Techne introduces a streamlined brand architecture that organizes its technologies into three focused portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™. The new brand structure reflects the scientific journey, connecting early discoveries to translational insight to clinical decision-making.

prnewswire.com - 2026-04-16 08:00:00

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Biogen Inc. (BIIB) and Techne (TECH). But which of these two stocks is more attractive to value investors?

zacks.com - 2026-04-15 12:40:43